刘小波+朱虹

[摘要] 目的 探讨恩替卡韦治疗慢性重型乙型肝炎的临床效果。 方法 选择本院2013年1月～2014年1月收治的慢性重型乙型肝炎患者96例，将其随机分为观察组和对照组，每组48例，均接受基础支持治疗，对照组加用拉米夫定治疗，观察组加用恩替卡韦治疗，对比两组的临床效果及治疗前后肝功能和血清HBV DNA改善情况。 结果 观察组总有效率为97.92％，高于对照组的83.33％（P<0.05）；观察组治疗后肝功能和血清HBV DNA明显优于对照组（P<0.05）。 结论 恩替卡韦治疗慢性重型乙型肝炎的临床效果显著，能改善患者的生活质量，值得临床推广应用。

[关键词] 慢性重型乙型肝炎；恩替卡韦；临床效果

[中图分类号] R512.6+2[文献标识码] A[文章编号] 1674-4721（2014）04（c）-0097-02

Clinical efficacy and security observation of entecavir in treatment of chronic severe hepatitis B

LIU Xiao-bo ZHU Hong

People′s Hospital of Jishui County in Jiangxi Province,Jishui 331600,China

[Abstract] Objective To investigate the clinical effect of entecavir in the treatment of chronic severe hepatitis B.Methods 96 cases of patients with chronic severe hepatitis B in our hospital from January 2013 to January 2014 were selected,and were randomly divided into observation group and control group,48 cases in each group.All patients were treated with basic treatment,the control group were treated with lamivudine,observation group were treated with entecavir.The clinical effect was compared between two groups,and the liver function and serum HBV DNA improvement was observed before and after treatment.Results The total effective rate was 97.92％ in the observation group,higher than 83.33％ in the control group (P<0.05);After treatment,the liver function and serum HBV DNA in the observation groups was better than that in the control group respectively (P<0.05).Conclusion The clinical effect of entecavir treatment for chronic severe hepatitis B is significant,can improve the quality of life of patients,is worthy of promotion.

[Key words] Chronic severe hepatitis B;Entecavir;Clinical effect

慢性重型乙型肝炎的发病率占乙型肝炎的1%左右，以青年居多[1]，不仅对患者的身体健康造成了严重的损害，甚至对患者的生命安全构成威胁。针对这种情况，本院对2013年1月～2014年1月收治的96例慢性重型乙型肝炎患者在接受基础支持治疗的前提下，给予拉米夫定和恩替卡韦治疗，探讨恩替卡韦治疗慢性重型乙型肝炎的临床效果及安全性。

1 资料与方法

1.1 一般资料

本研究96例患者均了解治疗给药方案并签署知情同意书，自愿服从治疗安排。患者在接受诊断期间，均出现不同程度的肝区不适、肝脏肿大、疲乏等临床表现，进行血液检查、肝功能检查后，确诊96例患者均符合慢性重型乙型肝炎的诊断标准[2]。采用随机数字表将96例患者分为观察组和对照组，观察组48例，其中男性34例，女性14例；年龄20～56岁，平均（35.4±6.4）岁；病程3个月～5年，平均（3.2±1.6）年。对照组48例，其中男性31例，女性17例；年龄21～58岁，平均（32.5±6.7）岁；病程1～5年，平均（3.5±1.8）年。两组患者的性别、年龄、病程、体重等一般资料比较，差异无统计学意义（P＞0.05），具有可比性。……